impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Brief Papers

 

Cutaneous manifestations in mevalonate kinase deficient patients treated with canakinumab

1, 2, 3, 4, 5

 

  1. University of Trieste, Italy. mariasoleconte@gmail.com
  2. Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  3. Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  4. University of Trieste and Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.
  5. University of Trieste and Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.

CER12367
2020 Vol.38, N°4
PI 0760, PF 0762
Brief Papers

purchase article

PMID: 32324125 [PubMed]

Received: 26/04/2019
Accepted : 21/11/2019
In Press: 23/04/2020
Published: 28/07/2020

Abstract

Canakinumab is a human monoclonal antibody anti-interleukin-1β, it is the only biologic drug approved to treat mevalonate kinase deficiency (MKD). Canakinumab injection can trigger several local cutaneous reactions, but also chronic-relapsing skin infections and other manifestations. We report three cases of unusual cutaneous manifestations in patients treated with canakinumab.

Rheumatology Article